Jazz Pharmaceuticals plc provided earnings guidance for the full year 2024. For the period, the company expected revenues to be in the range of $4,000 million to $4,200 million, net income of $385 million to $530 million and net income per diluted share to be in the range of $5.80 to $7.70.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
101.3 USD | -2.18% |
|
-5.12% | -17.67% |
01/07 | Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 3000E Growth Index | CI |
01/07 | Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 1000 Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.67% | 6.39B | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024